Related Experiment Video
Updated: Feb 16, 2026

HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries
Published on: March 31, 2019
Competing endogenous RNA network analysis of CD274, IL‑10 and FOXP3 co‑expression in laryngeal squamous cell
Juan Sun1, Meng Lian1, Hongzhi Ma1
1Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, P.R. China.
Abstract:
Laryngeal squamous cell carcinoma (LSCC) is one of the most common types of head and neck malignant tumor; however, there is a lack of effective molecular targets for therapy. The present study detected the expression of three immunity‑associated molecules [forkhead box (FOX)3, interleukin (IL)‑10 and cluster of differentiation (CD)274] in 133 LSCC samples using immunohistochemistry (IHC); subsequently, the association between their expression and the clinical characteristics of LSCC were analyzed. Spearman's rank correlation method, Kaplan‑Meier and Cox regression model were used to analyze the correlations of the three proteins and their clinical significance. StarBase and miRTarBase databases were used to establish the competitive endogenous (ce)RNA network of the three molecules. IHC demonstrated that the positive expression rates of FOXP3, IL‑10 and CD274 were 68.4, 73.7 and 58.6% in 133 LSCC samples, respectively. In addition, it was identified that the expression of the three proteins was closely correlated with the clinical characteristics of LSCC, including lymph node metastasis and prognosis (P<0.05). There was also a significant association of co‑expression between any two proteins (P<0.001). Furthermore, the expression levels of FOXP3, IL‑10 and CD274 were negatively associated with the survival rate of patients with LSCC (P<0.05). The results of a Cox regression model suggested that the three proteins were prognostic risk factors for LSCC (P<0.05). The ceRNA network revealed that 10 microRNAs (miRs; including miR‑16‑5p and miR‑214‑3p), 123 long non‑coding RNAs (including X‑inactive specific transcript, H19 and metastasis associated lung adenocarcinoma transcript 1) and 408 circular RNAs (including ATP‑binding cassette subfamily C member 1 hsa_circ_001569 and ISY1 splicing factor homolog hsa_circ_001859) may regulate the expression of FOXP3, IL‑10 and CD274. The data generated from the present study may increase the understanding of the immune escape mechanisms of LSCC and may be beneficial for the development of a specific immunotherapy.
Insights
This study investigated the expression of FOXP3, IL-10, and CD274 in laryngeal squamous cell carcinoma (LSCC), finding they correlate with poor prognosis and may serve as therapeutic targets for immunotherapy.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Laryngeal squamous cell carcinoma (LSCC) lacks effective molecular therapeutic targets.
- Understanding immune escape mechanisms in LSCC is crucial for developing new treatments.
Purpose of the Study:
- To detect the expression of FOXP3, IL-10, and CD274 in LSCC samples.
- To analyze the association between these molecules and LSCC clinical characteristics and prognosis.
- To establish a competitive endogenous RNA (ceRNA) network regulating these molecules.
Main Methods:
- Immunohistochemistry (IHC) was used to detect protein expression in 133 LSCC samples.
- Statistical analyses included Spearman's rank correlation, Kaplan-Meier, and Cox regression.
- Bioinformatic databases (StarBase, miRTarBase) were used for ceRNA network construction.
Main Results:
- High positive expression rates of FOXP3 (68.4%), IL-10 (73.7%), and CD274 (58.6%) were observed.
- Expression correlated significantly with lymph node metastasis and prognosis (P<0.05).
- Co-expression of any two proteins was significant (P<0.001), and all three were negatively associated with survival (P<0.05).
Conclusions:
- FOXP3, IL-10, and CD274 are prognostic risk factors for LSCC.
- These molecules are implicated in LSCC immune escape mechanisms.
- The identified ceRNA network provides potential regulatory insights for LSCC immunotherapy development.
